Of the studies using FISH to evaluate EGFR copy number change or amplification, two were in gastric cancer patients, demonstrating poor survival in the 4.88 % of European patients with amplification, however survival outcome was not assessed in 29 % EGFR amplified Chinese gastric cancer patients [24, 25]. The gene discussed is EGFR; the disease is gastric cancer.